High Yield Overview
Soft Tissue Masses
Identify the dangerous lump before anyone cuts it
Deepdeep to fascia is a referral red flag
Greater than 5 cmsize threshold used in referral pathways
MRI firstdefines anatomy before biopsy
MDTsarcoma care is planned before treatment
Triage Categories
Clearly benign superficial lesion
PatternTypical lipoma, epidermoid cyst, ganglion or haematoma with reassuring features.
TreatmentObserve, ultrasound or local treatment only when the diagnosis is secure.
Indeterminate mass
PatternUnclear diagnosis, atypical imaging, persistent pain or recurrence.
TreatmentMRI and specialist review before excision.
Sarcoma red-flag mass
PatternDeep, greater than 5 cm, enlarging, painful or recurrent after excision.
TreatmentMRI with contrast, sarcoma unit referral and planned core biopsy.
Unplanned excision
PatternMass removed before appropriate imaging/biopsy and final histology shows sarcoma.
TreatmentUrgent sarcoma referral, staging, MRI of tumour bed and planned re-excision pathway.
Critical Must-Knows
- The safe default is: image and refer before cutting. A suspected sarcoma should not be drained, shelled out or excised as a lump.
- Deep, enlarging, painful, recurrent or greater than 5 cm masses need sarcoma-pathway thinking. Small superficial lesions can still be malignant when behaviour is atypical.
- MRI is obtained before biopsy. It defines compartment, neurovascular relationships, bone involvement, viable biopsy target and the future resection field.
- Biopsy route is part of the operation. The tract must be planned so it can be removed with the tumour.
- Unplanned excision changes prognosis and reconstruction. The tumour bed is contaminated until proven otherwise and usually needs specialist re-excision planning.
Clinical Pearls
- "Do not reassure a patient because the mass is painless; many sarcomas are painless.
- "Ultrasound can confirm a simple cyst or superficial lipoma, but MRI is the key test for an indeterminate or deep mass.
- "Needle biopsy should target viable enhancing tissue, not central necrosis.
- "The first operation is often the best chance to preserve margins, function and reconstructive options.
Never excise an indeterminate deep mass to get the diagnosis
An excisional biopsy of a suspected sarcoma contaminates the tumour bed, alters MRI interpretation, may force wider re-excision and can compromise limb-sparing reconstruction. If the diagnosis is not confidently benign, stop and refer.
Mnemonic
DEEPSarcoma Red Flags
D
Deep to fascia
A deep mass is not treated like a superficial lipoma.
E
Enlarging
Progressive growth is more important than a single size measurement.
E
Exceeds 5 cm
Greater than 5 cm is a common referral threshold.
P
Painful or persistent
Pain, recurrence or persistence after injury needs imaging.
Memory Hook:DEEP masses need deeper thinking.
Mnemonic
IMAGEInitial Safety Pathway
I
Inspect behaviour
Growth rate, pain, recurrence and depth.
M
MRI before biopsy
Map compartments, vessels, nerve, bone and viable target.
A
Avoid excision
Do not shell out an indeterminate lesion.
G
Guide the biopsy
Core biopsy route must sit in the planned resection field.
E
Escalate to sarcoma unit
MDT planning improves diagnosis and definitive treatment.
Memory Hook:IMAGE before incision.
Mnemonic
RESCUEUnplanned Excision Response
R
Refer urgently
Do not perform a second local procedure.
E
Evaluate tumour bed
MRI of the surgical bed and staging imaging.
S
Stage disease
Chest imaging and subtype-specific staging.
C
Confirm histology
Specialist pathology review of the excised specimen.
U
Understand contamination
Scar, drain site and haematoma may be contaminated.
E
Excise appropriately
Plan re-excision, radiotherapy and reconstruction through MDT.
Memory Hook:RESCUE the pathway after a whoops procedure.
Overview and Epidemiology
Most soft tissue lumps are benign, but the clinical cost of missing sarcoma is high. The common error is not ignorance of sarcoma subtypes; it is treating an indeterminate lump as a harmless lump before appropriate imaging and referral.
Soft tissue sarcoma is uncommon compared with benign lipoma, cyst, haematoma and muscle injury. That rarity creates danger: a surgeon or general clinician may see many benign lumps for every sarcoma and become overconfident. The safer approach is to recognise behaviour that is not benign.
Benign-Looking Does Not Mean Safe
| Feature | Reassuring Pattern | Concerning Pattern |
|---|---|---|
| Size | Small and stable. | Greater than 5 cm or increasing over time. |
| Depth | Clearly superficial and mobile above fascia. | Deep to fascia, intramuscular or fixed to deeper tissues. |
| Pain | Pain linked to trauma and resolving. | Persistent, night, progressive or unexplained pain. |
| Previous treatment | No recurrence after clearly benign treatment. | Recurrent after aspiration, drainage or excision. |
| Imaging | Classic cyst or lipoma on appropriate imaging. | Heterogeneous, infiltrative, vascular, necrotic or deep lesion. |
Pathophysiology
Soft tissue sarcomas arise from mesenchymal tissues such as muscle, fat, fibrous tissue, vessels, peripheral nerve sheath or undifferentiated soft tissue. The clinical pathway is similar across subtypes because the first decisions are anatomical and oncological: where is the mass, what does it involve, how should it be sampled, and can it be removed with a planned margin?
Important biological concepts:
- Pseudocapsule: many sarcomas compress adjacent tissue but are not truly encapsulated. Shelling out the mass leaves microscopic disease.
- Reactive zone: oedema, haematoma and post-biopsy change can contain tumour cells and may need inclusion in the resection field.
- Compartment anatomy: deep masses can involve muscle compartments, neurovascular bundles, periosteum, joint capsule or bone.
- Necrosis: large high-grade sarcomas may contain necrotic areas; biopsy should target viable enhancing tissue.
- Skip and metastatic risk: staging is subtype- and grade-dependent, but chest imaging is central for many extremity sarcomas because lung metastasis is common.
The sarcoma is not the only tissue at risk
The biopsy tract, drain site, haematoma cavity, contaminated planes and previous scar may become part of the definitive resection. That is why the first procedure must be planned.
Classification
Classification in the initial clinic is not about memorising every histological subtype. It is about sorting the mass into a safe management pathway.
Clinical Risk Categories
| Category | Typical Features | Action |
|---|---|---|
| Low-risk superficial mass | Small, superficial, soft, mobile, stable and imaging-classic benign. | Observe, ultrasound or local treatment when diagnosis is secure. |
| Indeterminate mass | Unclear diagnosis, atypical features or discordant clinical/imaging findings. | MRI and specialist review before excision. |
| High-risk mass | Deep, enlarging, painful, recurrent or greater than 5 cm. | MRI with contrast and sarcoma referral. |
| Post-excision sarcoma | Sarcoma diagnosed after unplanned excision. | Urgent sarcoma MDT, staging, tumour-bed MRI and re-excision planning. |
Clinical Presentation
History
Ask precise questions that decide risk and pathway:
- When was the mass first noticed?
- Is it enlarging, stable or fluctuating?
- Was there real trauma, or did trauma simply draw attention to the mass?
- Is there pain, night pain, neurological symptom, vascular symptom or functional loss?
- Has it been aspirated, drained, injected or excised before?
- Is there a history of cancer, radiotherapy, genetic syndrome or immunosuppression?
- Are there systemic features such as weight loss, fever or multiple masses?
Examination
Examine the mass as a surgical field, not only as a lump.
Examination Sequence
| Step | How To Examine | What It Means |
|---|---|---|
| Look | Expose the whole limb and compare sides. Inspect scars, swelling, skin tethering, venous prominence, ulceration and previous drain sites. | Scars and drain sites may define contaminated tissue if sarcoma is confirmed. |
| Feel | Define size in centimetres, depth, temperature, tenderness, consistency, fluctuation and relation to fascia. | Deep or fixed masses are higher risk than mobile superficial lesions. |
| Move | Move adjacent joints and contract nearby muscles while palpating the mass. | A mass that moves with muscle may be intramuscular; joint restriction may indicate periarticular involvement. |
| Neurovascular | Document pulses, capillary refill, sensation, motor power and Tinel sign when near major nerves. | Nerve or vessel involvement changes biopsy route, resection plan and counselling. |
| Regional staging | Check regional nodes for selected subtypes and examine chest/abdomen only as clinically indicated. | Most extremity sarcomas metastasise haematogenously, but some subtypes involve nodes. |
Investigations
Investigations To Order
| Investigation | How To Request It | What It Answers |
|---|---|---|
| Ultrasound | Use for clearly superficial lesion or to confirm cystic versus solid nature. | May identify simple cyst or lipoma, but cannot safely stage a deep indeterminate mass. |
| MRI with contrast | MRI of the whole involved anatomical compartment with skin markers over the mass. | Depth, size, compartment, margins, neurovascular/bone/joint relationship, necrosis and biopsy route. |
| Plain radiographs | Request regional x-rays if calcification, bone pain, periosteal reaction or deep mass near bone. | Mineralisation, bone erosion, periosteal reaction or alternate diagnosis. |
| Chest CT | Sarcoma staging after suspicion or diagnosis, according to sarcoma team pathway. | Pulmonary metastases, especially in high-grade extremity sarcoma. |
| Core biopsy | Image-guided core biopsy after MRI, planned with treating sarcoma team. | Histology, grade, molecular tests and treatment planning. |
Management
Management is pathway-based. The most important decision is often what not to do: do not incise, drain, aspirate repeatedly or excise an indeterminate mass outside a sarcoma plan.
Initial Management
| Scenario | Safe Action | Avoid |
|---|---|---|
| Classic benign superficial lesion | Treat locally only when diagnosis is secure and behaviour is benign. | Ignoring growth or atypical imaging. |
| Indeterminate superficial mass | Ultrasound or MRI depending clinical risk; refer if not confidently benign. | Office excision to find out what it is. |
| Deep or red-flag mass | MRI with contrast and sarcoma referral before biopsy. | Incisional biopsy, drainage or excision outside the resection plan. |
| Mass with neurovascular symptoms | Urgent imaging and specialist review. | Delay because the skin looks normal. |
Complications and Pitfalls
Common Failures
| Failure | Why It Matters | Corrective Action |
|---|---|---|
| Unplanned excision | Leaves residual microscopic disease and contaminates the surgical bed. | Refer urgently, restage, MRI tumour bed and plan re-excision. |
| Poor biopsy route | Forces wider resection or risks local recurrence. | Discuss route with sarcoma surgeon before biopsy. |
| Biopsy before MRI | Distorts anatomy with bleeding and post-procedure change. | MRI first unless an emergency diagnosis changes priorities. |
| Misdiagnosing haematoma | A sarcoma may bleed or be noticed after trauma. | Re-image persistent or enlarging haematoma-like lesions. |
| Underestimating reconstruction | Margins may require skin, muscle, nerve, vessel, bone or joint reconstruction. | Plan MDT reconstruction before excision. |
How to explain referral to a patient
Explain that referral does not mean the lump is definitely cancer. It means the lump has features that make specialist imaging and biopsy safer. The goal is to avoid the wrong first operation.
Evidence Signals
UK soft tissue sarcoma guideline
Key Findings:
- Soft tissue masses that are increasing in size, greater than 5 cm, deep to fascia or painful should be treated as malignant until proven otherwise.
- MRI and specialist referral are central before biopsy and treatment.
- Management should occur through specialist sarcoma services.
Clinical Implication: The referral threshold is deliberately sensitive because the harm of missed sarcoma is high.
Limitation: Guideline recommendations combine evidence and expert consensus for rare tumours.
Source: Dangoor et al., Clinical Sarcoma Research, 2016
ESMO-EURACAN-GENTURIS guideline
Key Findings:
- Diagnosis and treatment of sarcoma should be planned within specialist multidisciplinary teams.
- MRI is the preferred local imaging modality for extremity and trunk soft tissue sarcoma.
- Biopsy should be planned so that the tract can be removed during definitive surgery.
Clinical Implication: The surgeon must think about the definitive operation before taking tissue.
Limitation: Recommendations vary by sarcoma subtype, site and available expertise.
Source: Casali et al., Annals of Oncology, 2021
Biopsy hazards
Key Findings:
- Biopsy errors can change treatment and increase morbidity.
- Poor incision placement, contamination, inadequate sample and wrong biopsy type are major preventable errors.
- Biopsy should be planned with the treating tumour surgeon.
Clinical Implication: Biopsy is not a minor procedure; it is the first oncological operation.
Limitation: Older landmark series, but principles remain central to sarcoma care.
Source: Mankin et al., Journal of Bone and Joint Surgery, 1982
Unplanned excision
Key Findings:
- Residual disease after unplanned excision of extremity soft tissue sarcoma is common.
- Unplanned excision frequently requires re-excision and may increase reconstructive complexity.
- Early specialist referral after a whoops procedure is essential.
Clinical Implication: A scar from a 'lump excision' may represent contaminated tissue requiring oncological resection.
Limitation: Single-centre referral experience; exact rates vary by tumour and pathway.
Source: Noria et al., Journal of Bone and Joint Surgery, 1996
Clinical Scenarios
Use these scenarios to practise clinical reasoning and management decisions
CLINICAL SCENARIOStandard
CLINICAL PROMPT
"A 48-year-old patient has a painless enlarging thigh mass. It is about 8 cm, firm and deep to fascia. The skin is normal."
PRACTICAL APPROACH
I would treat this as a sarcoma red-flag mass until proven otherwise. I would not excise or biopsy it in clinic. I would document size, depth, mobility, neurovascular status and functional effect, then request MRI with contrast of the involved compartment with skin marker. I would refer to a sarcoma unit before biopsy. Biopsy should be image-guided core biopsy after MRI, with the route planned so it can be excised at definitive surgery. Staging and treatment would then be directed by the sarcoma MDT.
KEY CLINICAL POINTS
Deep and greater than 5 cm are red flags.
MRI before biopsy.
Refer before excision.
COMMON PITFALLS
✗Reassuring because it is painless.
✗Office excision to get diagnosis.
✗Biopsy route not planned with definitive resection.
FURTHER QUESTIONS
"What MRI features would you report?"
"Where should the biopsy tract be placed?"
"How would you counsel the patient?"
CLINICAL SCENARIOAdvanced
CLINICAL PROMPT
"A patient is referred after local excision of a presumed lipoma. Final histology shows high-grade soft tissue sarcoma with involved margins."
PRACTICAL APPROACH
This is an unplanned excision. I would stop further local procedures and refer urgently to a sarcoma MDT. I would obtain the operation note, pathology slides/blocks, imaging if any, and details of scar, drain and haematoma. I would arrange MRI of the tumour bed and staging chest imaging according to sarcoma protocol. Management usually involves planned re-excision of the contaminated tumour bed including scar and biopsy/excision tract, with radiotherapy and reconstruction considered by MDT. I would counsel that the previous procedure may have increased the extent of tissue needing removal.
KEY CLINICAL POINTS
Unplanned excision contaminates the field.
Restage and image the tumour bed.
Re-excision and adjuvant treatment are MDT decisions.
COMMON PITFALLS
✗Simple surveillance after involved-margin sarcoma excision.
✗Re-opening the scar for another incomplete excision.
✗Ignoring drain sites or haematoma spread.
FURTHER QUESTIONS
"What tissue is included in re-excision?"
"How does radiotherapy timing affect reconstruction?"
"What information do you need from the first operation?"
References
- Dangoor A, Seddon B, Gerrand C, Grimer R, Whelan J, Judson I. UK guidelines for the management of soft tissue sarcomas. Clin Sarcoma Res. 2016;6:20. doi:10.1186/s13569-016-0060-4.
- Casali PG, Abecassis N, Aro HT, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32(11):1348-1365. doi:10.1016/j.annonc.2021.07.006.
- Mankin HJ, Lange TA, Spanier SS. The hazards of biopsy in patients with malignant primary bone and soft-tissue tumors. J Bone Joint Surg Am. 1982;64(8):1121-1127.
- Noria S, Davis A, Kandel R, et al. Residual disease following unplanned excision of soft-tissue sarcoma of an extremity. J Bone Joint Surg Am. 1996;78(5):650-655.
- Grimer RJ, Carter SR, Tillman RM, et al. Unplanned excision of soft tissue sarcoma. J Bone Joint Surg Br. 2001;83(2):203-206.
- Venkatesan M, Richards CJ, McCulloch TA, et al. Inadvertent surgical resection of soft tissue sarcomas. Eur J Surg Oncol. 2012;38(4):346-351. doi:10.1016/j.ejso.2011.12.002.
Soft Tissue Mass Referral Cheat Sheet
Clinical summary
Red Flags
- •Deep to fascia
- •Greater than 5 cm
- •Enlarging
- •Painful or persistent
- •Recurrent after treatment
Safe Workup
- •Document size, depth and neurovascular status
- •MRI with contrast before biopsy
- •Chest staging after suspicion or diagnosis
- •Sarcoma unit referral
- •Core biopsy planned in resection field
Do Not Do
- •Do not drain an indeterminate mass
- •Do not shell out a deep lump
- •Do not biopsy before MRI
- •Do not place a transverse biopsy tract
- •Do not observe unexpected sarcoma histology
"Deep, enlarging, painful, recurrent or greater than 5 cm masses need MRI and sarcoma referral before biopsy or excision."